$CBAY News
Last published 4mo ago
- 4mo agoACOGMISTCBAYONCTAlpha Cognition Announces Election of Dr. Robert Wills as Chairman of the BoardBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced
- 1y agoACOGCBAYMISTONCTAlpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John HavensBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment
- 2y agoCBAYApproval of Livdelzi, Nda #217899 (Type 1 - New Molecular Entity)FDA Approved DrugsApproval Date: 08/14/2024; Drug Name: Livdelzi, Nda #217899; Active Ingredients: SELADELPAR; Company: Cymabay Therapeutics Inc; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 217899
- 2y agoCBAYGILDGilead Sciences Announces Completion of Acquisition of CymaBayBusiness WireAcquisition Reinforces Gilead's Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (NASDAQ:GILD) today announced the completion of the previously announced transaction
- 2y agoCBAYCymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary CholangitisGlobeNewswireNEWARK, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today
- 2y agoCBAYCymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate UpdateGlobeNewswireGilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. U.S. FDA accepted seladelpar NDA for priority review, and seladelpar marketing
- 2y agoCBAYThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary CholangitisPR NewswireCymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic...
- 2y agoAMAMDOORCBAYWISHKuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoCBAYCymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary CholangitisPR NewswireCymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic...
- 2y agoCBAYGILDGilead Sciences Expands Liver Portfolio With Acquisition of CymaBay TherapeuticsBusiness Wire-- Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review and Anticipated U.S. Approval in Third Quarter of 2024 -- -- Seladelpar Phase 3
- 2y agoCBAYCymaBay Therapeutics to Participate in Upcoming Investment ConferencesGlobeNewswireNEWARK, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today
- 2y agoCBAYCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEWARK, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high
- 2y agoCBAYNew Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's SeladelparPR NewswireCymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic...
- 2y agoCBAYCymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024GlobeNewswireNEWARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today
- 2y agoCBAYCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEWARK, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high
- 2y agoCBAYCymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary CholangitisPR NewswireCymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic...
- 2y agoCBAYCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEWARK, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high
- 2y agoCBAYCymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting®PR NewswireCymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic...
- 3y agoCBAYCymaBay Therapeutics, Inc. (CBAY) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoCBAYCymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate UpdateGlobeNewswireAnnounced top-line results from RESPONSE Phase 3 study in PBC where seladelpar met the primary and two key secondary endpoints with high statistical significance. Seladelpar granted revised Breakthrough Therapy
- 3y agoCBAYCymaBay Therapeutics to Present at Upcoming Investment ConferencesGlobeNewswireNEWARK, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today
- 3y agoCBAYCymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary CholangitisGlobeNewswireNEWARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today
- 3y agoCBAYCymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023GlobeNewswireNEWARK, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today
- 3y agoCBAYCymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023GlobeNewswireCholestatic pruritus expert leads plenary discussion of correlated decreases in serum IL-31 levels and pruritus among patients with PBC treated with seladelpar A second presentation of baseline trial data suggests that
- 3y agoCBAYSeladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or With Compensated CirrhosisGlobeNewswireNEWARK, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today
- 3y agoCBAYCymaBay's RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023GlobeNewswireResults from the RESPONSE registrational study to be highlighted in oral presentation on Monday, November 13th Fifth oral late-breaking presentation of seladelpar results at The Liver Meeting® NEWARK, Calif.,
- 3y agoCBAYCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high
- 3y agoCBAYCymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary CholangitisGlobeNewswireAFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation Data will be used to support post-marketing regulatory requirements for seladelpar's accelerated
- 3y agoCBAYCymaBay Therapeutics to Present at the Cantor Global Healthcare ConferenceGlobeNewswireNEWARK, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today
- 3y agoCBAYCymaBay Announces Closing of Upsized $258.7 Million Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireNEWARK, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases
- 3y agoCBAYCymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireNEWARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases
- 3y agoCBAYCymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireNEWARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases
- 3y agoCBAYCymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary CholangitisPR NewswirePrimary composite endpoint at 12 months of serum alkaline phosphatase and bilirubin was met by 61.7% of patients treated with seladelpar 10 mg vs. 20.0% of placebo treated patients (p<0.0001) Normalization of alkaline
- 3y agoCBAYCymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023GlobeNewswireNEWARK, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today
- 3y agoCBAYCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEWARK, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high
- 3y agoCBAYCymaBay Reports Second Quarter and Six Months Ended June 30, 2023 Financial Results and Provides Corporate UpdateGlobeNewswireTop-line data from RESPONSE Phase 3 study in PBC expected by end of September 2023 IDEAL clinical trial actively recruiting Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif.,
- 3y agoCBAYCymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 LevelsPR NewswireAdditional data presented at The International Liver Congress™ 2023 show clinical risk factors for PBC disease progression present in a broader population of UDCA-treated PBC patients Preclinical data points to
- 3y agoCBAYCymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023PR NewswireTwo abstracts focus on the unique mechanism of action of seladelpar; a third focuses on characterizing patient risk of PBC disease progression NEWARK, Calif., June 7, 2023 /PRNewswire/ -- CymaBay Therapeutics, Inc.
- 3y agoCBAYCymaBay Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireHarish Shantharam, proven leader in building financial organizations to prepare for successful commercialization, appointed as Chief Financial Officer Results from ENHANCE phase 3 global study of seladelpar in
- 3y agoCBAYCymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023GlobeNewswireNEWARK, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet
- 3y agoCBAYCymaBay Names Harish Shantharam Chief Financial OfficerGlobeNewswireProven Leader in Building Financial Organizations to Prepare Company for Successful Commercialization Planning for Seladelpar Launch as it Completes Development and Regulatory Submissions NEWARK, Calif., May 09, 2023
- 3y agoCBAYCymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)GlobeNewswireNEWARK, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and
- 3y agoCBAYCymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQGlobeNewswireNEWARK, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high
- 3y agoCBAYCymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate UpdateGlobeNewswireNEWARK, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high
- 3y agoCBAYCymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023GlobeNewswireNEWARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high
- 3y agoCBAYCymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare ConferenceGlobeNewswireNEWARK, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high
- 3y agoCBAYCymaBay Therapeutics to Present at the SVB Securities Global Biopharma ConferenceGlobeNewswireNEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high
- 3y agoCBAYCymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireNEWARK, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high
- 3y agoCBAYCymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireNEWARK, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high
- 3y agoCBAYCymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireNEWARK, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high